Study identifier:D133FR00101
ClinicalTrials.gov identifier:NCT02321046
EudraCT identifier:N/A
CTIS identifier:N/A
An epidemiOlogy study to deteRmine the prevalence of EGFR muTations in RUSsian patients with advanced NSCLC (ORTUS)
Non-small Cell Lung Cancer
N/A
No
-
All
26
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2020 by AstraZeneca
AstraZeneca
-
This is a multicentre, non-interventional, prospective study to be carried out in representative oncology departments / institutions in order to determine the prevalence of EGFR mutations in treatment-naive Russian patients with cytologically verified advanced NSCLC in Russia.
This is a multicentre, non-interventional, prospective study to be carried out in representative oncology departments / institutions in order to determine the prevalence of EGFR mutations in treatment-naive Russian patients with cytologically verified advanced NSCLC in Russia. No additional procedures besides those already used in the routine clinical practice will be applied to the patients. Treatment assignment will be done according to the current practice. It is planned to enrol approximately 300 subjects in Russian Federation. Approximately 60 EGFR m+ (mutation-positive) patients will be followed for 1.5 years. EGFR mutations rate before treatment in cytology and plasma samples in treatment-naive patients with advanced NSCLC in Russia is considered as the primary outcome variable in this study.
Location
Location
Arkhangelsk, Russia, Russian Federation
Location
Vladivostok, Russia, Russian Federation
Location
Irkutsk, Russia, Russian Federation
Location
Kemerovo, Russia, Russian Federation
Location
Krasnodar, Russia, Russian Federation
Location
Krasnoyarsk, Russia, Russian Federation
Location
Moscow, Russia, Russian Federation
Location
Novisibirsk, Russia, Russian Federation
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.